» Articles » PMID: 17618306

The Contribution of Cyclooxygenase-2 to Endocannabinoid Metabolism and Action

Overview
Journal Br J Pharmacol
Publisher Wiley
Specialty Pharmacology
Date 2007 Jul 10
PMID 17618306
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

The development of sensitive analytical methods for measurement of endocannabinoids, their metabolites, and related lipids, has underlined the complexity of the endocannabinoid system. A case can be made for an 'endocannabinoid soup' (akin to the inflammatory soup) whereby the net effect of a pathological state and/or a pharmacological intervention on this system is the result not only of changes in endocannabinoid levels but also of their metabolites and related compounds that affect their function. With respect to the metabolism of anandamide and 2-arachidonoylglycerol, the main hydrolytic enzymes involved are fatty acid amide hydrolase and monoacylglycerol lipase. However, other pathways can come into play when these are blocked. Cyclooxygenase-2 derived metabolites of anandamide and 2-arachidonoylglycerol have a number of properties, including effects upon cell viability, contraction of the cat iris sphincter (an effect mediated by a novel receptor), mobilization of calcium and modulation of synaptic transmission. Nonsteroidal anti-inflammatory agents, whose primary mode of action is the inhibition of cyclooxygenase, can also interact with the endocannabinoid system both in vitro and in vivo. Other enzymes, such as the lipoxygenase and cytochrome P450 oxidative enzymes, can also metabolize endocannabinoids and produce biologically active compounds. It is concluded that sensitive analytical methods, which allow for measurement of endocannabinoids and related lipids, should provide vital information as to the importance of these alternative metabolic pathways when the primary hydrolytic endocannabinoid metabolizing enzymes are inhibited.

Citing Articles

Reactive spinal glia convert 2-AG to prostaglandins to drive aberrant astroglial calcium signaling.

Docs K, Balazs A, Papp I, Szucs P, Hegyi Z Front Cell Neurosci. 2024; 18:1382465.

PMID: 38784707 PMC: 11112260. DOI: 10.3389/fncel.2024.1382465.


Arc Regulates Transcription of Genes for Plasticity, Excitability and Alzheimer's Disease.

Leung H, Foo G, VanDongen A Biomedicines. 2022; 10(8).

PMID: 36009494 PMC: 9405677. DOI: 10.3390/biomedicines10081946.


The fundamental role of the endocannabinoid system in endometrium and placenta: implications in pathophysiological aspects of uterine and pregnancy disorders.

Maia J, Fonseca B, Teixeira N, Correia-da-Silva G Hum Reprod Update. 2020; 26(4):586-602.

PMID: 32347309 PMC: 7317288. DOI: 10.1093/humupd/dmaa005.


Targeting Peripherally Restricted Cannabinoid Receptor 1, Cannabinoid Receptor 2, and Endocannabinoid-Degrading Enzymes for the Treatment of Neuropathic Pain Including Neuropathic Orofacial Pain.

Hossain M, Ando H, Unno S, Kitagawa J Int J Mol Sci. 2020; 21(4).

PMID: 32093166 PMC: 7073137. DOI: 10.3390/ijms21041423.


Novel COX-2 products of -3 polyunsaturated fatty acid-ethanolamine-conjugates identified in RAW264.7 macrophages.

de Bus I, Zuilhof H, Witkamp R, Balvers M, Albada B J Lipid Res. 2019; 60(11):1829-1840.

PMID: 31455615 PMC: 6824491. DOI: 10.1194/jlr.M094235.


References
1.
Guindon J, Loverme J, De Lean A, Piomelli D, Beaulieu P . Synergistic antinociceptive effects of anandamide, an endocannabinoid, and nonsteroidal anti-inflammatory drugs in peripheral tissue: a role for endogenous fatty-acid ethanolamides?. Eur J Pharmacol. 2006; 550(1-3):68-77. DOI: 10.1016/j.ejphar.2006.08.045. View

2.
Collaco-Moraes Y, Aspey B, Harrison M, de Belleroche J . Cyclo-oxygenase-2 messenger RNA induction in focal cerebral ischemia. J Cereb Blood Flow Metab. 1996; 16(6):1366-72. DOI: 10.1097/00004647-199611000-00035. View

3.
Berglund B, Boring D, Howlett A . Investigation of structural analogs of prostaglandin amides for binding to and activation of CB1 and CB2 cannabinoid receptors in rat brain and human tonsils. Adv Exp Med Biol. 2000; 469:527-33. DOI: 10.1007/978-1-4615-4793-8_77. View

4.
Maione S, Bisogno T, de Novellis V, Palazzo E, Cristino L, Valenti M . Elevation of endocannabinoid levels in the ventrolateral periaqueductal grey through inhibition of fatty acid amide hydrolase affects descending nociceptive pathways via both cannabinoid receptor type 1 and transient receptor potential vanilloid.... J Pharmacol Exp Ther. 2005; 316(3):969-82. DOI: 10.1124/jpet.105.093286. View

5.
Barth F, Millan J, Derocq J, Casellas P, Congy C, Oustric D . SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J Pharmacol Exp Ther. 1998; 284(2):644-50. View